OakChart

BlossomHill Therapeutics Inc

BLSMHealthcare·Biotechnology·USA·Small·NASD·Nov 11 • 12:11 PM ET

15.41+1.17 (8.22%)
2026-11-11 18:12 CET
Market cap
452.62 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-23.76 USD m
Free cash flow, TTM
-23.23 USD m
EPS diluted, TTM
-0.75
P/E
-
Compare

Price

BLSM against its 20 and 50-day averages
2050miss
15.0020.0025.00879K1.8MAug 26Sep 26Oct 26Nov 26BLSMclose 15.4120-day 14.4150-day 18.2015.4152w high52w low

44.9% under the 52-week high of 27.99 on 21 Sep 2026. 52-week low 11.02 on 5 Nov 2026. Last 15 sessions, 59.1% high to low

Profile

BLSM
52-week range, 26% of the way up
11.0227.99

Blossomhill Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It engages in the development of small molecule medicines for unmet medical needs in cancer treatment. The company was founded on June 22, 2020 and is headquartered in San Diego, CA.

Employees63
IPOAug 07, 2026
ATR, 14d1.73
Rel volume0.79
Short float2.61%
Insider own28.93%
Inst own21.33%

Snapshot

6 groups

Valuation

Index-
Market Cap489.81M
Enterprise Value674.62M
Income-
Sales-
Book/sh-5.50
Cash/sh3.00
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees63
IPOAug 07, 2026

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B-
P/C5.14
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio5.26
Current Ratio5.26
Debt/Eq-
LT Debt/Eq-
Option/ShortNo / Yes

Earnings

EPS (ttm)-
EPS next Y-
EPS next Q-0.89
EPS this Y-
EPS next Y-
EPS next 5Y-
EPS past 3/5Y- -
Sales past 3/5Y- -
EPS Y/Y TTM-
Sales Y/Y TTM-
EPS Q/Q-
Sales Q/Q-
EarningsSep 18 BMO
EPS/Sales Surpr.-844.92% -

Ownership

Insider Own28.93%
Insider Trans20.65%
Inst Own21.33%
Inst Trans18.11%
ROA-
ROE-
ROIC-
Gross Margin-
Oper. Margin-
Profit Margin-
SMA206.92%
SMA50-15.34%
SMA200-13.95%
Trades-

Technical

Shs Outstand31.78M
Shs Float22.59M
Short Float2.61%
Short Ratio2.96
Short Interest0.59M
52W High27.99 -44.94%
52W Low11.02 39.84%
Volatility15.52% 12.02%
ATR (14)1.73
RSI (14)50.43
Beta-
Rel Volume0.79
Avg Volume199.10K
Volume69,236

Performance

Perf Week24.47%
Perf Month-0.45%
Perf Quarter-5.75%
Perf Half Y-
Perf YTD-2.16%
Perf Year-
Perf 3Y-
Perf 5Y-
Perf 10Y-
Recom1.00
Target Price35.40
Prev Close14.24
Price15.41
Change %8.22%

Analyst ratings

latest 3 of 3
DateActionAnalystRating changeTargetImplied
Sep 01, 2026InitiatedJJP MorganOverweight$28+81.7%
Sep 01, 2026InitiatedHH.C. WainwrightBuy$35+127.1%
Sep 01, 2026InitiatedGGuggenheimBuy$30+94.7%

Peers

Mkt cap
TickerCompanyMkt cap
AVBPArriVent BioPharma Inc698.77M
CGEMCullinan Therapeutics Inc725.92M
ORICORIC Pharmaceuticals Inc922.03M
BDTXBlack Diamond Therapeutics Inc92.21M
NUVBNuvation Bio Inc1.52B
KURAKura Oncology Inc694.82M
RLAYRelay Therapeutics Inc4.38B
IDYAIdeaya Biosciences Inc3.16B
ERASErasca Inc5.79B
TNGXTango Therapeutics Inc4.36B

Insider trading

7 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
GORDON CARL LDirectorAug 10 '26Buy16.00625,00010,000,0002,714,279Aug 12 04:46 PM
ORBIMED ADVISORS LLCDirectorAug 10 '26Buy16.00625,00010,000,0002,714,279Aug 12 04:43 PM
Schmid John P.DirectorAug 10 '26Buy16.006,00096,0006,000Aug 10 06:35 PM
Chen BihuaDirectorAug 10 '26Buy16.00312,5005,000,0003,614,034Aug 10 06:32 PM
Keyes Jason AChief Financial OfficerAug 10 '26Buy16.0070011,200700Aug 10 06:27 PM
Liptak Vincent PaulGeneral CounselAug 07 '26Buy15.802,50039,500109,212Aug 10 06:26 PM
Liptak Vincent PaulGeneral CounselAug 10 '26Buy16.002,20035,200111,412Aug 10 06:26 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VXFVanguard Extended Market Index ETFAUM: 30.47B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
VTWGVanguard Russell 2000 Growth Index ETFAUM: 1.41B
VTWVVanguard Russell 2000 Value Index ETFAUM: 1.29B
VTHRVanguard Russell 3000 Index ETFAUM: 4.81B

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-09-18-8.750-0.926-8.7550.000.005
2026Q12026-06-03-1.298--0.6610.00--
2026Q3---0.887--0.005
2026Q4---0.949--0.005
2027Q1---0.920--0.004
2027Q2---0.883--0.004
2027Q3---0.825--0.004
2027Q4---0.830--0.004

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
No annual earnings.

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-09-184000.000.000.00
2026Q3S2026-09-023000.000.000.00
2026Q3S2026-08-313000.000.000.00
2026Q3R2026-09-21101-0.92-0.92-0.92
2026Q3R2026-09-18101-0.92-0.92-0.92
2026Q3R2026-09-02100-0.89-0.89-0.89
2026Q3R2026-08-31100-0.89-0.89-0.89
2026Q3E2026-11-09514-0.89-0.93-0.82
2026Q3E2026-09-23513-0.87-0.93-0.73
2026Q3E2026-09-21512-0.87-0.92-0.73
2026Q3E2026-09-18511-0.87-0.92-0.73
2026Q3E2026-09-02500-0.87-0.92-0.73
2026Q3E2026-08-31500-0.87-0.92-0.73
2026Q2S2026-08-313000.000.000.00

Estimate history

EPS, annual-0.966-1.905
Period20242025
EPS, quarterly-0.33-0.417-0.661-0.748
PeriodQ1 '25Q2 '25Q1 '26Q2 '26
Sales, annual00
Period20242025
Sales, quarterly0000
PeriodQ1 '25Q2 '25Q1 '26Q2 '26
Shares, annual31.78531.78531.785
Period20242025MRQ
Shares, quarterly31.78531.78531.78531.785
PeriodQ1 '25Q2 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY
Total Revenue0.000.000.00
Cost of Goods Sold Incl. D&A0.120.440.35
Gross Profit-0.12-0.44-0.35
Selling, General and Administrative Excl. Other24.5563.5836.05
Research and Development21.3656.1431.81
Other Operating Expense0.000.000.00
Operating Income-24.67-64.02-36.40
Unusual Expense0.000.000.00
Net Income Before Taxes-23.76-60.55-30.70
Income Taxes0.000.000.00
Consolidated Net Income-23.76-60.55-30.70
Net Income From Continuing Operations-23.76-60.55-30.70
Net Income-23.76-60.55-30.70
EPS (Recurring)-0.75-1.91-0.97
EPS (Basic, Before Extraordinaries)-0.75-1.91-0.97
EPS (Diluted)-0.75-1.91-0.97
EBITDA-24.55-63.58-36.05
Non-Operating Income (Expense)0.913.475.71
Other After Tax Adjustments0.000.000.00
Stock Option Compensation Expense0.581.090.50
Shares Outstanding31.7831.7831.78
Market Capitalization452.62452.62-

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q22025Q1
Total Revenue0.000.000.000.00
Cost of Goods Sold Incl. D&A0.120.120.100.09
Gross Profit-0.12-0.12-0.10-0.09
Selling, General and Administrative Excl. Other24.5521.9814.0011.37
Research and Development21.3619.9012.539.57
Other Operating Expense0.000.000.000.00
Operating Income-24.67-22.11-14.10-11.45
Unusual Expense0.000.000.000.00
Net Income Before Taxes-23.76-21.01-13.24-10.48
Income Taxes0.000.000.000.00
Consolidated Net Income-23.76-21.01-13.24-10.48
Net Income From Continuing Operations-23.76-21.01-13.24-10.48
Net Income-23.76-21.01-13.24-10.48
EPS (Recurring)-0.75-0.66-0.42-0.33
EPS (Basic, Before Extraordinaries)-0.75-0.66-0.42-0.33
EPS (Diluted)-0.75-0.66-0.42-0.33
EBITDA-24.55-21.98-14.00-11.37
Non-Operating Income (Expense)0.911.100.860.98
Other After Tax Adjustments0.000.000.000.00
Stock Option Compensation Expense0.580.320.250.23
Shares Outstanding31.7831.7831.7831.78
Market Capitalization452.62---

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY
Cash & Short Term Investments136.68100.15
Short Term Receivables0.000.00
Inventories0.000.00
Other Current Assets2.144.03
Total Current Assets138.83104.17
Net Property, Plant & Equipment21.651.59
Total Investments and Advances0.000.00
Deferred Tax Assets4.330.16
Other Assets2.501.02
Total Assets167.30106.94
Short Term Debt Incl. Current Port. of LT Debt0.010.53
Accounts Payable2.310.85
Other Current Liabilities13.165.40
Total Current Liabilities15.486.77
Long Term Debt279.22172.88
Provision for Risks Charges0.000.00
Deferred Tax Liabilities4.330.16
Other Liabilities0.000.00
Total Liabilities299.03179.82
Non-Equity Reserves0.000.00
Preferred Stock - Carrying Value0.000.00
Common Equity-131.73-72.88
Total Shareholders Equity-131.73-72.88
Accumulated Minority Interest0.000.00
Total Equity-131.73-72.88
Total Liabilities & Stockholders Equity167.30106.94
Book Value Per Share-4.14-2.29
Tangible Book Value Per Share-4.14-2.29
Full-Time Employees63-
Price to Book Ratio-2.59-
Return on Assets-44.16-
Return on Invested Capital-41.06-30.69
Quick Ratio8.9715.38
Current Ratio8.9715.38

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY
Net Income-23.76-60.55-30.70
Depreciation0.120.440.35
Other Funds (Non Cash)0.982.381.20
Funds from Operations-22.66-57.74-29.14
Extraordinary Item0.000.000.00
Changes in Working Capital-0.5810.81-2.27
Cash from Operating Activities-23.23-46.92-31.42
Capital Expenditures0.00-1.07-0.09
Net Assets From Acquisitions0.000.000.00
Sale of Fixed Assets and Businesses0.000.000.00
Purchase or Sale of Investments0.000.000.00
Purchase of Investments0.000.000.00
Sale Or Maturity of Investments0.000.000.00
Other Uses0.000.000.00
Other Sources0.000.000.00
Cash from Investing Activities0.00-1.07-0.09
Cash Dividends Paid0.000.000.00
Preferred Dividends (Cash Flow)0.000.000.00
Change in Capital Stock2.6184.5317.56
Repurchase of Common Pref Stock0.000.000.00
Sale of Common Pref Stock2.6184.5317.56
Proceedsfrom Stock Options2.6184.5317.56
Issuance or Reduction of Debt, Net0.000.000.00
Change in Long Term Debt0.000.000.00
Issuance of Long Term Debt0.000.000.00
Reduction of Long Term Debt0.000.000.00
Net Financing Active Other Cash Flow0.000.000.00
Other Financing Activities Uses0.000.000.00
Cash from Financing Activities2.6184.5317.56
Net Change in Cash-20.6336.53-13.95
Free Cash Flow-23.23-47.99-31.51
Deferred Taxes & Investment Tax Credit-0.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q22025Q1
Cash & Short Term Investments95.38116.00--
Short Term Receivables0.000.00--
Inventories0.000.00--
Other Current Assets2.593.22--
Total Current Assets97.97119.22--
Net Property, Plant & Equipment20.6921.21--
Total Investments and Advances0.000.00--
Other Assets5.482.98--
Total Assets124.13143.41--
Short Term Debt Incl. Current Port. of LT Debt1.150.49--
Accounts Payable3.935.38--
Other Current Liabilities13.5410.30--
Total Current Liabilities18.6216.18--
Long Term Debt279.05279.35--
Provision for Risks Charges0.000.00--
Other Liabilities1.250.00--
Total Liabilities298.91295.53--
Non-Equity Reserves0.000.00--
Preferred Stock - Carrying Value0.000.00--
Common Equity-174.78-152.12--
Total Shareholders Equity-174.78-152.12--
Accumulated Minority Interest0.000.00--
Total Equity-174.78-152.12--
Total Liabilities & Stockholders Equity124.13143.41--
Book Value Per Share-5.50-4.79--
Tangible Book Value Per Share-5.50-4.79--
Full-Time Employees6963--
Price to Book Ratio-2.59---
Return on Invested Capital-22.79-16.51--
Quick Ratio5.267.37--
Current Ratio5.267.37--

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q22025Q1
Net Income-23.76-21.01-13.24-10.48
Depreciation0.120.120.100.09
Other Funds (Non Cash)0.980.650.560.41
Funds from Operations-22.66-20.23-12.59-9.98
Extraordinary Item0.000.000.000.00
Changes in Working Capital-0.58-0.703.44-1.00
Cash from Operating Activities-23.23-20.94-9.14-10.98
Capital Expenditures0.00-0.01-0.59-0.40
Net Assets From Acquisitions0.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.00
Purchase or Sale of Investments0.000.000.000.00
Purchase of Investments0.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.00
Other Uses0.000.000.000.00
Other Sources0.000.000.000.00
Cash from Investing Activities0.00-0.01-0.59-0.40
Cash Dividends Paid0.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.00
Change in Capital Stock2.610.270.050.04
Repurchase of Common Pref Stock0.000.000.000.00
Sale of Common Pref Stock2.610.270.050.04
Proceedsfrom Stock Options2.610.270.050.04
Issuance or Reduction of Debt, Net0.000.000.000.00
Change in Long Term Debt0.000.000.000.00
Issuance of Long Term Debt0.000.000.000.00
Reduction of Long Term Debt0.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.00
Other Financing Activities Uses0.000.000.000.00
Cash from Financing Activities2.610.270.050.04
Net Change in Cash-20.63-20.68-9.69-11.34
Free Cash Flow-23.23-20.95-9.74-11.38

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-302.61%0.6M22.6M226.76K
2026-10-152.15%0.5M22.6M248.62K
2026-09-302.13%0.5M22.3M271.18K
2026-09-150.62%0.1M22.3M261.47K
2026-08-310.52%0.1M21.5M321.54K
2026-08-140.52%0.1M21.4M613.09K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-09-1810-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-09-188-KCurrent report2026-09-18SEC
2026-09-158-KCurrent report2026-09-15SEC
2026-08-18SCHEDULE 13DSEC
2026-08-17SCHEDULE 13GSEC
2026-08-14SCHEDULE 13GSEC
2026-08-13SCHEDULE 13DSEC
2026-08-124Statement of changes in beneficial ownership of securities2026-08-10SEC
2026-08-124Statement of changes in beneficial ownership of securities2026-08-10SEC
2026-08-104Statement of changes in beneficial ownership of securities2026-08-06SEC
2026-08-104Statement of changes in beneficial ownership of securities2026-08-06SEC
2026-08-104Statement of changes in beneficial ownership of securities2026-08-06SEC
2026-08-104Statement of changes in beneficial ownership of securities2026-08-06SEC
2026-08-104Statement of changes in beneficial ownership of securities2026-08-06SEC
2026-08-104Statement of changes in beneficial ownership of securities2026-08-06SEC
2026-08-104Statement of changes in beneficial ownership of securities2026-08-10SEC
2026-08-104Statement of changes in beneficial ownership of securities2026-08-06SEC
2026-08-104Statement of changes in beneficial ownership of securities2026-08-06SEC
2026-08-10S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-08-108-KCurrent report2026-08-10SEC
2026-08-07424B4SEC
2026-08-06EFFECTEffectiveness filing by commission orderSEC
2026-08-063Initial statement of beneficial ownership of securities2026-08-06SEC
2026-08-063Initial statement of beneficial ownership of securities2026-08-06SEC
2026-08-063Initial statement of beneficial ownership of securities2026-08-06SEC
2026-08-063Initial statement of beneficial ownership of securities2026-08-06SEC
2026-08-063Initial statement of beneficial ownership of securities2026-08-06SEC
2026-08-063Initial statement of beneficial ownership of securities2026-08-06SEC
2026-08-063Initial statement of beneficial ownership of securities2026-08-06SEC
2026-08-063Initial statement of beneficial ownership of securities2026-08-06SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-0825.18M700
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
FMR LLC3.23%
GEODE CAPITAL MANAGEMENT, LLC0.37%
Monashee Investment Management LLC0.25%
Squarepoint Ops LLC0.07%
CITIGROUP INC0.00%
UBS Group AG0.00%

Funds

Fund% owned
Select Biotechnology Portfolio1.13%
Multi-Manager Small Cap Equity Strategies Fund0.24%
Small Cap Value Fund0.06%
VANGUARD RUSSELL 2000 INDEX FUND0.03%
BlackRock Event Driven Equity Fund0.01%
VANGUARD RUSSELL 2000 GROWTH INDEX FUND0.00%
VANGUARD RUSSELL 2000 VALUE INDEX FUND0.00%
VANGUARD RUSSELL 3000 INDEX FUND0.00%

OakChart. BLSM. Cached 15 minutes.

Some panels did not load: news.